You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬孚生物(300482.SZ):2019年淨利預增20%-30%
格隆匯 01-20 19:50

格隆匯1月20日丨萬孚生物(300482.SZ)披露2019年度業績預告,公司預計2019年1-12月歸屬於上市公司股東的淨利潤為約3.69億元–約4億元,同比增長20%-30%。業績變動原因如下:

1、公司主營業務繼續保持強勁的增長勢頭。國內免疫熒光平台的心臟標誌物、炎症因子等高毛利產品實現較快增長。免疫膠體金平台在國內流感檢測需求不斷上升的帶動下,實現了超高速的增長。美國子公司積極對毒檢業務進行產品升級和戰略調整,截止到報告期末業務基本恢復正常。除美國以外的其他海外地區總體也保持了穩定的增長。在新業務方面,化學發光、血氣、凝血、乾式生化等均實現了戰略突破,在產品推廣和渠道建設方面打下了良好的基礎。

2、商譽減值:根據《企業會計準則第8號-資產減值》及相關會計政策規定,公司期末對收購形成的商譽進行系統性減值測試,發現公司收購的控股子公司達成生物科技發展(蘇州)有限公司存在商譽減值的可能性,預計本期計提的商譽減值總額為3500萬元至4500萬元。最終商譽減值準備計提的金額將由公司聘請的具備證券期貨從業資格的評估機構及審計機構進行評估和審計後確定。

若剔除掉商譽減值的影響,公司歸屬於上市公司股東的淨利潤為約4.04億元至約4.45億元,比上年同期增長約31.37%至44.62%。

3、歸屬於上市公司股東的非經常性損益金額為2500萬元左右,主要為政府補助和投資收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account